No profile data available.
Cartesian Therapeutics, Inc. (RNAC) is a healthcare company in the metabolic process treatment drugs industry, based in Frederick, United States, with about 75 full-time employees.
It reported revenue of $2.80 million for fiscal year 2025, down 92.8% from fiscal year 2024, and net income of -$130.30 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $78,000, down 92.9% from a year before. Its market capitalization was $213.45 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases.
Cartesian Therapeutics reported $2.80 million in revenue for fiscal year 2025, down 92.8% from $38.91 million in fiscal year 2024. In Q1 2026 revenue was $78,000.
$213.45 million as of October 9, 2026.
Listed companies of a similar size in the same industry (metabolic process treatment drugs) include Amarin Corporation plc (AMRN), Camp4 Therapeutics Corp (CAMP), Protalix BioTherapeutics, Inc. (PLX), Xortx Therapeutics Inc. (XRTX).